black box warning for glp 1 agonists Thyroid Cancer: A on Anti-obesity Medications?! Nutritional Care for Adults With

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

Studies have suggested that in addition to diabetes, GLP-1R agonists may also have a beneficial effect on many other diseases such as cardiovascular disease, central nervous disorder, and tumors ( 4.2 Cardiovascular disease The latest research has found that GLP-1R is widely expressed in the cardiovascular system and is involved in intracellular metabolism and signal transduction

Voluntary paid subscriptions all go to support Scripps Research.

The new science of GLP-1: effects beyond glucose control

By molecule class, the market is divided into semaglutide, tirzepatide, and other molecules

6 (2009): 589595, 10.1111/j.1463-1326.2008.01023.x